Google
Trusted Resources: News & Events
Latest announcements and gatherings
Novel Sickle Cell Drug Causes Radical Results in End of Life Patients
This week the FDA approved a novel treatment for sickle cell disease, a serious and sometimes deadly disease that affects around 100,000 Americans. The treatment was found to exceptionally improve the health and quality of life in the “end of life” patients involved in the trials, and experts believe that upon release, it may do much to improve the lives of sickle cell patients throughout the world.
Oxbryta is an inhibitor of deoxygenated sickle hemoglobin polymerization and was granted Accelerated Approval. This classification allows the FDA to quickly approve drugs for serious conditions. The drug’s trial consisted of 274 patients with sickle cell disease who received different doses of the medication or a placebo, a press release explained.
Results showed that the medication was able to increase the hemoglobin response rate in patients far more than those in the placebo group. This is important as sickle cell affects the hemoglobin, a type of red blood cell, and leads to some of the disease’s devastating effects.
+myBinderRelated Content
-
Bluebird bio acquires Durham, NC, manufacturing site for lentiviral vector productionbluebird bio said today it has acquired ...
-
Osteonecrosis of the Femoral Head in Sickle Cell Disease: Prevalence, Comorbidities and Surgical Outcomes in Califor...Introduction: Osteonecrosis of the femor...
-
Gene-Edited ‘Supercells’ Make Progress In Fight Against Sickle Cell DiseaseDoctors are reporting the first evidence...
-
Prolong Pharma’s Sanguinate Shows Promise in Reverting Shape of Red Blood Cells in SCDProlong Pharmaceuticals’ investigation...
-
Patterns of opioid use in sickle cell diseasePain, the hallmark complication of sickl...
-
Kids Who Need Sickle Cell Meds Don’t Always Get ThemLess than a fifth of U.S. children with ...
-
Phase 3 Trial of Rivipansel in Treating SCD Pain Crisis Fails to Meet Goals, Pfizer AnnouncesThe Phase 3 RESET trial testing the effe...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.